Co-Authors
This is a "connection" page, showing publications co-authored by FREDRICK B HAGEMEISTER and SELVI THIRUMURTHI.
Connection Strength
0.101
-
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol. 2022 03; 23(3):406-415.
Score: 0.051
-
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. J Clin Oncol. 2022 01 10; 40(2):202-212.
Score: 0.050